A detailed history of Parkside Financial Bank & Trust transactions in Xencor Inc stock. As of the latest transaction made, Parkside Financial Bank & Trust holds 18 shares of XNCR stock, worth $370. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18
Previous 13 38.46%
Holding current value
$370
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$15.7 - $21.65 $78 - $108
5 Added 38.46%
18 $0
Q4 2023

Feb 01, 2024

SELL
$16.53 - $21.42 $3,091 - $4,005
-187 Reduced 93.5%
13 $0
Q3 2023

Nov 13, 2023

BUY
$20.08 - $25.39 $2,128 - $2,691
106 Added 112.77%
200 $4,000
Q2 2023

Aug 15, 2023

BUY
$24.77 - $29.9 $198 - $239
8 Added 9.3%
94 $2,000
Q1 2023

May 04, 2023

SELL
$25.95 - $36.95 $1,894 - $2,697
-73 Reduced 45.91%
86 $2,000
Q4 2022

Feb 13, 2023

SELL
$24.79 - $30.86 $1,487 - $1,851
-60 Reduced 27.4%
159 $4,000
Q3 2022

Nov 01, 2022

BUY
$24.62 - $32.44 $3,643 - $4,801
148 Added 208.45%
219 $6,000
Q2 2022

Jul 13, 2022

BUY
$19.74 - $29.01 $927 - $1,363
47 Added 195.83%
71 $2,000
Q1 2022

May 13, 2022

SELL
$26.68 - $41.63 $5,522 - $8,617
-207 Reduced 89.61%
24 $1,000
Q4 2021

Feb 14, 2022

BUY
$33.67 - $43.44 $740 - $955
22 Added 10.53%
231 $9,000
Q3 2021

Oct 29, 2021

BUY
$30.65 - $35.68 $4,260 - $4,959
139 Added 198.57%
209 $7,000
Q2 2021

Aug 06, 2021

SELL
$34.33 - $44.68 $3,810 - $4,959
-111 Reduced 61.33%
70 $2,000
Q4 2020

Feb 09, 2021

BUY
$36.63 - $47.63 $3,809 - $4,953
104 Added 135.06%
181 $8,000
Q3 2020

Nov 06, 2020

BUY
$30.09 - $43.02 $2,316 - $3,312
77 New
77 $3,000
Q2 2020

Aug 10, 2020

SELL
$27.76 - $33.42 $360 - $434
-13 Closed
0 $0
Q1 2020

May 05, 2020

SELL
$20.69 - $37.79 $868 - $1,587
-42 Reduced 76.36%
13 $0
Q4 2019

Jan 30, 2020

BUY
$32.75 - $41.43 $1,801 - $2,278
55 New
55 $2,000

Others Institutions Holding XNCR

About Xencor Inc


  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.23B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Parkside Financial Bank & Trust Portfolio

Follow Parkside Financial Bank & Trust and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parkside Financial Bank & Trust, based on Form 13F filings with the SEC.

News

Stay updated on Parkside Financial Bank & Trust with notifications on news.